Vital Medical Center
- Address
- lock Available on a paid plan
Immune System Diseases and Rheumatology
At Vital Medical Center in Veszprem, a large share of the clinical trial work focuses on autoimmune and inflammatory diseases, especially rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and polymyalgia rheumatica. These studies are designed to test new treatment options, compare them with existing therapies, and better understand how to reduce pain, stiffness, and disease activity.
- Research on rheumatoid arthritis includes studies of symptom control, joint protection, and long-term treatment safety.
- Psoriatic arthritis trials are evaluating therapies aimed at easing joint inflammation and improving daily function.
- Axial spondyloarthritis and related conditions are being studied to find better ways to manage ongoing inflammation and mobility problems.
- Polymyalgia rheumatica research is exploring approaches to maintain remission and reduce relapses.
The site is also involved in studies that assess how well treatments work after prior therapy has not been enough, helping guide more personalized care for people with chronic rheumatic diseases.
Skin and Connective Tissue Diseases
Another important area of research at Vital Medical Center is dermatology, with trials centered on plaque psoriasis and atopic dermatitis. These studies aim to improve skin symptom control, reduce inflammation, and evaluate whether new therapies can offer better relief for people living with moderate to severe disease.
- Plaque psoriasis studies are testing treatments for skin clearance, symptom reduction, and durability of response.
- Atopic dermatitis research focuses on easing itching, redness, and overall skin irritation.
- Some trials look at patients with more challenging forms of psoriasis, including involvement of special areas or higher body weight.
- Several studies also examine the long-term safety and tolerability of emerging therapies for chronic skin disease.
This work reflects a strong focus on finding better options for people whose skin and connective tissue diseases remain difficult to manage with standard care.
Immune System Processes and Systemic Lupus Erythematosus
The center also contributes to research on immune system processes through multiple studies in systemic lupus erythematosus SLE. These trials are intended to measure whether new therapies can lower disease activity, improve overall control, and support safer long-term treatment for people with this complex autoimmune condition.
- SLE trials are evaluating treatments for adults with moderate to severe disease activity.
- Research includes efforts to improve symptom control and reduce flare-related burden.
- Some studies focus on treatment effectiveness in patients already receiving standard lupus care.
- Long-term follow-up is also being used to better understand safety and sustained benefit.
This area shows the site’s interest in advancing care for difficult autoimmune diseases where treatment response can vary widely.
Musculoskeletal Diseases and Joint Disorders
Research at Vital Medical Center also includes trials in musculoskeletal diseases, particularly knee osteoarthritis. These studies are focused on easing pain, improving movement, and comparing treatment approaches that may help people with joint damage and chronic discomfort.
- Knee osteoarthritis studies are examining ways to reduce pain and improve function.
- Some trials compare different treatment options to see which may offer better symptom relief.
- Research in this area is aimed at supporting quality of life for people with long-standing joint problems.
- Safety and tolerability remain important goals alongside symptom improvement.
Together, these studies add a practical orthopedic and rheumatologic dimension to the site’s broader clinical research portfolio.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 38 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Eli Lilly & Co.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vital Medical Center
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 38 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Jnj-77242113 | 2 | Unknown | 2023-12-05 | 2023-12-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
